Biotechnology developer Magenta Therapeutics, which exploits Harvard research, has launched with series A funding provided by investors including Alphabet.
Magenta Therapeutics, a US-based stem cell biotechnology developer that has licensed research conducted at Harvard University, emerged from stealth yesterday with $48.5m in series A funding from investors including conglomerate Alphabet.
The round was co-led by venture capital firms Third Rock Venture and Atlas Venture, which had incubated Magenta Therapeutics since 2014. Alphabet, which invested through its GV unit, participated alongside diversified holding group Access Industries and Partners Innovation Fund.
Magenta is developing treatments for autoimmune diseases, genetic blood disorders…
